Neuroblastoma Patients’ KIR and KIR-ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children’s Oncology Group

PURPOSE: In 2010, a Children’s Oncology Group (COG) phase III randomized trial for high-risk neuroblastoma patients (ANBL0032) demonstrated improved event-free survival (EFS) and overall survival (OS) following treatment with an immunotherapy regimen of dinutuximab, GM-CSF, IL-2, and isotretinoin co...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Cancer Res
Prif Awduron: Erbe, Amy K, Wang, Wei, Carmichael, Lakeesha, Kim, KyungMann, Mendonça, Eneida A, Song, Yiqiang, Hess, Dustin, Reville, Patrick K, London, Wendy B, Naranjo, Arlene, Hank, Jacquelyn A, Diccianni, Mitchell B, Reisfeld, Ralph A, Gillies, Stephen D, Matthay, Katherine K, Cohn, Susan L, Hogarty, Michael D, Maris, John M, Park, Julie R, Ozkaynak, M. Fevzi, Gilman, Andrew L, Yu, Alice L, Sondel, Paul M
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2017
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5754221/
https://ncbi.nlm.nih.gov/pubmed/28972044
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-1767
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg